04:17 PM EST, 11/04/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) reported Q3 non-GAAP net income late Monday of $4.38 per diluted share, up from $4.08 a year earlier.

Analysts polled by Capital IQ expected $4.13.

Product revenue for the quarter ended Sept. 30 was $2.77 billion, up from $2.48 billion a year earlier.

Analysts surveyed by Capital IQ forecast $2.69 billion.

The biotech firm now expects fiscal 2024 revenue of $10.8 billion to $10.9 billion, compared with $10.65 billion to $10.85 billion previously. Analysts polled by Capital IQ are looking for $10.76 billion.

Shares were up 1.5% in recent after-hours activity.

Price: 480.00, Change: +7.20, Percent Change: +1.52